You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
SBC: VASADE BIOSCIENCES, INC. Topic: NIAProject Summary: Alzheimer’s Disease is associated with metabolic dysfunction, glucose and insulin resistance, oxidative stress, mitochondrial dysfunction, and reduced exercise capacity. Oxidative stress and mitochondrial dysfunction correlate with the development of beta-amyloid (Aβ) deposits, one of the hallmarks of AD that begin years before the onset of memory and cognitive decline. Moreove ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Next-generation nanomedicine for acute ischemic stroke
SBC: Nanomuse, LLC Topic: NINDSABSTRACT / PROJECT SUMMARYAcute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary injury caused by ischemia-reperfusion injury. To solve this problem, many neuroprotective drugs were trial ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups
SBC: JP LABORATORIES INC Topic: 300Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.
SBC: Zena Therapeutics Inc. Topic: NIDAOpioid use disorder (OUD) is highly prevalent among individuals with diagnosed anxiety disorders with more than 60% of individuals with OUD reporting a lifetime anxiety disorder. Co-occurring anxiety is linked to earlier and more rapid progression into OUD, poorer treatment outcomes, and high probability of co-use of other substances, particularly benzodiazepines (BZDs). BZDs are currently the sta ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Advanced Quantitative Magnetic Resonance Imaging Phantoms for Nonalcoholic Fatty Liver Disease
SBC: CALIMETRIX LLC Topic: NIBIBPROJECT SUMMARYThe overall goal of this Phase I proposal is to design and test the feasibility of novel magnetic resonance imaging (MRI) reference standards (“phantoms”) that are urgently needed for comprehensive and standardized quality assurance (QA) of quantitative MRI biomarkers of non-alcoholic fatty liver disease (NAFLD). We propose to develop 1) a quantitative MR elastography (MRE) stif ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Virtual Reality Technologies for Dynamic Balance Rehabilitation in People with Stroke
SBC: KOBUK TECHNOLOGIES LLC Topic: NICHDPROJECT SUMMARY/ABSTRACT This project aims to quantify and establish elements of immersive virtual reality (VR) software that, when paired with treadmill training, produce balance perturbations that can be scaled to improve dynamic balance and are tolerated by people with stroke. VR continues to be used as an interactive and engaging way for clinicians to interact with patients during physical the ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Framework for mHealth App Security and Privacy Analysis
SBC: UBITRIX INTERNATIONAL, INC. Topic: NLMPROJECT SUMMARY/ABSTRACT With the increased use of mobile health (mHealth) apps to improve health outcomes, protecting private health data is becoming increasingly important. These mHealth apps are offered by healthcare providers and used by patients for various reasons such as paying bills, scheduling appointments, sending messages to providers, accessing lab results, and viewing prescriptions an ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Neural organoid models of the immunological microenvironment of glioblastoma for drug discovery applications
SBC: STEM PHARM, INCORPORATED Topic: 102Project Summary/Abstract Glioblastoma (GBM) is the most prevalent primary brain tumor in adults with extremely poor survival rates and largely unchanged standard of care. While there are many challenges to developing better GBM treatments, one of the major challenges is the immune-suppressive environment commonly found within GBM tumors. This immune-suppressive nature results in a tumor that is no ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis
SBC: Prokaryotics, Inc. Topic: NIAIDWidespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a n ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Recombinant E-NTPDase for shock
SBC: Purine Pharmaceuticals Inc. Topic: 300SUMMARYInflammation after ischemia and reperfusion injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incident scene to treat hypovolemic shock do not completely prevent ischemia and reperfusion injury. Re-initiation of blood flow causes activation of several inflammatory mediators, suc ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health